Blog

IRVINE, CALIFORNIA / ACCESS Newswire / December 10, 2025 / iTrustCapital, a leading platform for alternative assets, today announced it has surpassed $16 billion in total crypto transaction volume. This milestone reflects a 60% increase in client activity over the past year and highlights the company’s continued momentum in the digital asset investing space. Achieved only two months after crossing the $15 billion mark, this accomplishment reflects the growing interest from individuals and businesses in making cryptocurrency a vital part of their investment, corporate, and retirement strategies.

“Reaching this milestone is a great way to close out a remarkable year for our team,” said Kevin Maloney, Chief Executive Officer of iTrustCapital. “As we head into 2026, we’re focused on expanding what’s possible for our clients and continuing to build secure, dependable access to digital assets. The year is poised to be a pivotal one for both the alternative asset and the traditional finance industries.”

Over the years, iTrustCapital has been consistently recognized for its platform, client experience, and ongoing commitment to innovation. The company was named the #1 Crypto IRA Platform in America at the 2021 IMA Impact Awards and received Best Crypto IRA Investment Platform USA at the 2022 Fintech Awards from Wealth & Finance International. In 2024, iTrustCapital ranked #162 on the Deloitte Technology Fast 500™, and earned the Crypto Award at the US Fintech Awards.

The strong performance continued in 2025, with iTrustCapital again recognized by the WebAwards for Best Cryptocurrency Website, receiving another Stevie Award for Achievement in Customer Experience, being named one of the 10 Most Innovative Companies of the Year by Business Honor, and earning the title of Top Crypto IRA Retirement Platform from Financial Services Review. The company also received the Impact Award for Digital Currency Company of the Year, adding to a growing list of industry honors.

iTrustCapital continues to demonstrate strong trust and satisfaction within its community, earning an “Excellent” 4.9-star rating from more than 12,000 client reviews.

Heading into 2026, the team is focused on building on their momentum with new features, expanded access, and continued improvements designed to support investors at every step. The company expects to follow non-IRA accounts with a stablecoin option and BTC lending product, both slated for Q1-2026.

About iTrustCapital

iTrustCapital is a leading fintech software platform for alternative assets. The company provides 24/7 access to digital assets, cryptocurrencies, and precious metals through self-directed, tax-advantaged IRA* and Non-IRA account options. Leveraging a highly secure closed-loop ecosystem and third-party U.S. banks and custodians, iTrustCapital provides greater asset protection and flexibility for a broad range of retail and institutional clients. The company has earned more than 12,000 excellent reviews from Google and Trustpilot, and has successfully executed more than $16B in crypto transactions to date.

For more information, visit itrustcapital.com.

*Some taxes may apply.

iTrustCapital is not an exchange, funding portal, custodian, trust company, licensed broker, dealer, broker-dealer, investment advisor, investment manager, or adviser in the United States or elsewhere. iTrustCapital is not affiliated with and does not endorse any particular digital asset, precious metal or investment strategy.

Digital assets are a speculative investment with risk of loss. iTrustCapital does not provide legal, investment or tax advice. We recommend seeking the advice of a qualified legal, investment or tax professional.

CONTACT:

Kona Bertolino
Senior Content Marketing Manager
info@itrustcapital.com
(562) 600-8399

SOURCE: iTrustCapital

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / December 10, 2025 / Some invitations carry more weight because of what happened before them. SMX’s (NASDAQ:SMX) new role as a featured presenter inside a NAFRA and American Chemistry Council program is one of those moments. It does not introduce the company to the sector. It confirms that the sector has already watched and liked how the technology performs. This is a return to a room that knows exactly what SMX brings to the table.

Earlier this year, SMX completed proof-of-concept trials for identifying and sorting flame-retardant plastic. These trials were conducted in a controlled, industrial configuration with NAFRA oversight. They were designed to answer the only question that matters at the beginning of any materials innovation. Can it work at speed, at scale, with precision that meets real-world demands.

Those trials delivered 99% to 100% accuracy at 3 m/s, including on carbon-black plastics that standard optical systems fail to reliably identify. They also validated SMX’s integrated stack using molecular markers, high-speed detection, and a digital passport that maintains identity throughout the life of the plastic. This created a foundation of demonstrated capability. It moved SMX out of the category of possibility to proven performance.

A Room That Represents the Industry’s Core Decision Makers

The new invitation places SMX in a small, curated forum with the people who define how flame-retardant materials are used, managed, and recycled in North America. These audiences are not passive observers. They shape standards, advise regulators, lead compliance frameworks, and influence how circularity infrastructure evolves across multiple industry segments.

This matters because NAFRA is not evaluating options in theory. They already watched the technology work. That makes this next meeting a progression rather than an introduction. When a standards-setting group invites a company back, the discussion shifts from feasibility to the practical questions of how a system could be deployed across the value chain.

Rooms like this also attract institutional and philanthropic capital groups that view circularity as infrastructure. They focus on systems that change outcomes, not marketing claims. They examine technologies that can support long-horizon improvements in traceability, compliance, and material recovery. SMX now sits in that conversation because the data already demonstrated its capability.

From Demonstration to the Implementation Conversation

The real story here is not the presentation slot itself. It is the stage of the relationship. SMX has already proven its ability to identify and sort BFR-containing plastics with an accuracy level the industry has not consistently achieved. That step is complete. The next step is to show what an operational rollout could look like when applied across supply chains that require both safety and compliance.

This is not a sales pitch. It is a strategic engagement. The people in this room are capable of shaping adoption pathways, evaluating how a technology integrates with existing recycling systems, and identifying opportunities for consistent traceability across plastic categories. They are the ones who recognize when a proof point is ready for the next conversation.

SMX enters this phase positioned to participate in discussions that influence long-term industry direction. The company is no longer establishing that its system works. It is demonstrating why it matters. The invitation signals that the progress made in earlier trials has brought SMX into the part of the process where leaders consider how to build on validated results.

A Step Forward That Reflects Real Momentum

The broader implications extend beyond flame-retardant plastics. Once a sector adopts a system that assigns molecular identities, the benefits naturally translate to adjacent categories. Identity becomes a norm. Auditable data becomes expected. Circularity becomes measurable instead of theoretical. This is why early validation inside a high-scrutiny material class carries so much strategic importance.

For SMX, this next engagement reinforces that molecular identity is shifting from an innovation to a viable structural tool. The company has built a platform that can document the life of a material, enable high-speed identification, and provide transparency aligned with regulatory trends in both North America and abroad. These are qualities that industry leaders consider essential when planning the future of recycling infrastructure.

The invitation confirms that SMX has reached a new stage. It is not simply demonstrating technology. It is participating in the dialogue that shapes how technology becomes part of a broader system. This is the progression every materials solution needs to reach, and SMX is now firmly inside that zone.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, events, or circumstances that SMX expects, believes, or anticipates will or may occur in the future, including statements relating to the Company’s business strategy, financial position, future operations, future revenues, projected costs, prospects, plans, and objectives of management, as well as statements regarding the Company’s liquidity position, capital needs, anticipated financing timelines, expected dilution, future share issuances, the anticipated use of proceeds, expected performance of the amended financing agreement, market conditions, adoption of the Company’s technology, commercial pipeline, regulatory approvals, industry trends, competitive position, and any assumptions underlying the foregoing, are forward-looking statements.

Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events and are subject to a number of risks, uncertainties, and factors that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks relating to: the Company’s ability to successfully execute its operating plans; the Company’s ability to obtain additional financing on acceptable terms or at all; the Company’s ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the trading price of the Company’s ordinary shares; dilution that may result from the Company’s existing financing arrangements; the Company’s ability to access capital under the standby equity purchase agreement and related amendments; the timing and occurrence of any closings under such agreements; the Company’s expectations regarding its financial runway and future capital needs; risks associated with the Company’s ability to scale its technology, secure customer adoption, or convert pilot programs into commercial deployments; risks relating to supply chain conditions and global economic trends; the Company’s dependence on key personnel; the Company’s ability to maintain intellectual property protection and defend against infringement claims; changes in applicable laws and regulations; general economic, political, and market conditions; risks relating to digital asset markets and the Company’s potential future acquisition or holding of digital assets; and other factors detailed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F and its subsequent reports filed with the SEC.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made and are not guarantees of future performance. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Actual results may differ materially from those anticipated due to various risks and uncertainties, and all forward-looking statements contained herein are qualified in their entirety by this cautionary statement.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

New open-source platform provides scale, cryptographic identity, permissions, and tamper-proof audit trails for autonomous software, replacing “god-mode” API keys.

TORONTO, ON / ACCESS Newswire / December 10, 2025 / AgentField today announced that it has emerged from stealth to do for AI agents what Kubernetes did for containers: turn them into scalable, governed production infrastructure. The new open-source platform solves the “coordination crisis” of autonomous software by assigning every agent a cryptographic identity, ensuring that when AI makes decisions, like spending money or touching data, it does so with enforceable permissions and mathematical proof of authority.

While designed for any developer deploying autonomous software, this foundation is particularly critical for high-stakes, high-throughput industries-finance, energy, healthcare, logistics, insurance, and critical infrastructure-where small errors can escalate instantly. Across the board, AI is moving out of the chatbot UI and into core systems: reading ledgers, reconciling transactions, and scheduling freight. However, traditional infrastructure cannot support this shift.

“Autonomous software turns your infrastructure into a digital workforce,” said Oktay Goktas, CEO of AgentField. “That workforce doesn’t log in once a day. It runs constantly in the background, fans out across hundreds of APIs, and executes critical operations at machine speed. You cannot manage millions of autonomous decisions with human-centric SSO or brittle API keys. The identity and orchestration layer has to be rebuilt for autonomous software.”

The “Coordination Crisis” of Autonomous Software

When an agent delegates a task, such as moving funds, updating a patient record, or re-routing a shipment, it triggers a chain of downstream actions where a single request cascades into dozens of autonomous decisions. Traditional authorization systems (OAuth, IAM) fail here because they were built for deterministic human workflows; relying on synchronous checks or broad API keys for software that reasons and acts autonomously causes the entire trust model to collapse.

AgentField solves this by combining Kubernetes-style orchestration with decentralized identity:

• Cryptographic Identity (DIDs): Every agent receives a W3C Decentralized Identifier.

• Verifiable Credentials: Agents issue tamper-proof proofs when delegating tasks. A supply chain agent can cryptographically prove it was authorized by a specific risk policy, and that its authority traces back through a chain of agents to an original human or system decision, without needing a central callback.

• Tamper-Proof Audits: Security teams get cryptographic receipts for every action, not just text logs.

“We are watching old assumptions break in real time,” said Santosh Kumar Radha, CTO of AgentField. “When a $250,000 transfer happens at 3:17 a.m., you need to know exactly who authorized it and under what policy. AgentField ensures that even if an agent functions autonomously five hops down a chain, its authority can be mathematically verified.”

Production Infrastructure for Thinking Software

AgentField provides the control plane for autonomous agents the way Kubernetes provides one for containers, but for identity-bearing, long-running intelligence. Beyond identity, AgentField provides the operational primitives needed to run stateful agents in production:

• Long-running execution: Support for agents that work on tasks for minutes or hours.

• Async orchestration: Built-in retries, webhook-based triggers, and backpressure handling for multi-agent workflows.

• Policy as Code: Access control and IAM policies are enforced by the control plane instead of prompts or ad-hoc scripts.

Most teams today silently reinvent this backend plumbing with brittle scripts and ad-hoc glue code. AgentField provides it as a coherent, production-grade control plane where trust travels with the agent across systems and organizations, an essential property of a real agent economy.

Open-Source Strategy & Availability

AgentField is launching as an Apache 2.0 open-source project available today on GitHub. The founders view open standards as critical for an “agent economy” where software from different vendors must coordinate trustlessly.

Backed by Panache Ventures and Brightspark Ventures, AgentField was founded by repeat entrepreneurs and PhD holders who previously built Agnostiq and its open-source platform Covalent, acquired by DataRobot in February 2025.

For more information, visit agentfield.ai.

ABOUT AGENTFIELD:

AgentField provides identity and scale infrastructure for autonomous software. Based in Toronto, the company builds the open-source foundations that give AI agents cryptographic identities, delegatable permissions, and production-grade orchestration. Founded by Oktay Goktas, PhD (CEO), and Santosh Kumar Radha, PhD (CTO), who previously built and sold Agnostiq to DataRobot in 2025. Learn more at agentfield.ai.

MEDIA CONTACT: Nina Pfister, MAG PR at nina@mooringadvisorygroup.com

SOURCE: AgentField

View the original press release on ACCESS Newswire

• CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA’s June deadline – 51 dogs enrolled to date; ~49 more expected

SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the U.S. Food and Drug Administration (FDA) has granted renewal of the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company’s prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy. The renewal of conditional approval is in effect until December 21, 2026.

“Canalevia-CA1 is an important prescription drug for the veterinary community and the thousands of dogs experiencing CID. We’re very pleased about this conditional approval renewal, which, per FDA regulations, is for the fifth and final allowable year of conditional approval for Canalevia-CA1 for the CID indication in dogs. When an animal drug receives conditional approval, the FDA requires that a confirmatory trial take place within 5 years to provide the substantial evidence of effectiveness required for full approval of the drug for the indication,” said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar’s Vice President of Preclinical and Nonclinical Studies. “As announced, our full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs is underway, and this recent conditional approval renewal was granted because we were able to demonstrate active progress toward generating this required data.”

“Diarrhea is a highly neglected and unmet medical need in dogs and people undergoing cancer treatment,” said Lisa Conte, Jaguar’s president and CEO. “Jaguar is deeply committed to supporting the quality of life of people and animals undergoing cancer treatment.”

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Canalevia^®-CA1

Canalevia-CA1 contains crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. Canalevia-CA1, currently conditionally approved by the FDA under application number 141-552, is a tablet that can be given orally twice a day for up to three days and can be used for home treatment of CID in dogs.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.¹ According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the US.

Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the company’s ongoing trial will provide the substantial evidence of effectiveness required for full approval of the drug for treatment of CID in dogs and will conclude in February 2026 with an approximate total of 100 dogs having participated. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

THE HAGUE, NL / ACCESS Newswire / December 10, 2025 / The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems.

© 2005 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon’ logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, “Nasdaq”), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.

GASA Media Contact
Metje van der Meer
Marketing Director
metje.vandermeer@gasa.org
+31 6 48456282

Nasdaq Contact:
Nick Eghtessad
Corporate Communications
nick.eghtessad@nasdaq.com
+ 1 929 996-8894

SOURCE: Global Anti-Scam Alliance

View the original press release on ACCESS Newswire

GE HealthCare and Tribun Health collaboration helps foster enterprise imaging and pathology for oncology

CHICAGO, ILLINOIS / ACCESS Newswire / December 10, 2025 / GE HealthCare (Nasdaq: GEHC) announced today that Sant’ Andrea University Hospital, a center of excellence affiliated with Sapienza University of Rome, has chosen the combined strength of GE HealthCare’s Enterprise Imaging platform and Tribun Health‘s CaloPix^® digital pathology solution to unify radiology and pathology into a seamless integrated, artificial intelligence (AI)-ready environment.

With GE HealthCare’s Datalogue^[1], including a vendor neutral archive (VNA), and Tribun Health’s award-winning digital pathology platform CaloPix^®, Sant’ Andrea is driving to the forefront of a new era in data-driven cancer care. GE HealthCare’s Datalogue helps unify and intelligently manage patient data, images and enterprise imaging content. The Tribun Health Suite is a leading AI-powered end-to-end computational pathology for diagnostics, prognosis and drug development.

Sant’ Andrea, a public university hospital known for its leadership in oncology and translational research, manages a high volume of complex pathology and imaging cases. This initiative supports its broader mission of accelerating diagnostics, advancing multidisciplinary collaboration, and improving outcomes for patients facing cancer. Sant’ Andrea Hospital is the first in Lazio to implement full digital pathology, with an investment of nearly €1.5 million, about €800,000 of which came from the National Recovery and Resilience Plan.

“The oncology care pathway is one of the most complex with multiple steps involving a variety of specialists, complex tools, frequent decisions and large data sets,” said Scott Miller, CEO of Solutions for Enterprise Imaging, GE HealthCare. “Sant’ Andrea’s enterprise imaging implementation will help streamline the oncology care pathway across the enterprise and support clinical teams delivering the best care to their patients.”

“This marks a significant achievement for both Tribun Health and GE HealthCare, and a promising step forward for the future of diagnostic medicine,” said Jean-François Pomerol, CEO of Tribun Health. “Through this collaboration, we’re demonstrating how global partnerships can drive measurable local impact-enhancing efficiency in pathology labs, improving clinical decision-making, and accelerating the delivery of critical insights to patients undergoing cancer care.”

The digital pathology solutions will help focus on making pathology diagnostic faster and easier for healthcare providers at the point of care. With GE HealthCare’s Datalogue, pathology diagnostic outputs are integrated into an enterprise imaging platform, and can help create a one stop shop for unified clinical data available to clinicians to form decisions. A unified view of clinical patient data is a key asset in oncology for a multi-disciplinary team to be powered by the patient related information and collaborate to define best treatment for the patient in the oncology care pathway.

“This implementation allows doctors to make faster, more informed decisions and represents a fundamental step in our hospital’s digital transformation,” said Francesca Milito, General Director of AOU Sant’ Andrea. “By unifying radiology and pathology, we improve access to clinical data and create an integrated environment where doctors can make faster and more informed decisions for every cancer patient.”

Visit here to learn more about GE HealthCare’s enterprise imaging solutions.

^[1]Datalogue is a solution which consists of multiple products, mainly Enterprise Archive and Centricity Universal Viewer Zero Footprint Client.

GE HealthCare Media Contact:

Linh Dinh
M +408 275 5682
Linh.Dinh@gehealthcare.com

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies^™.

Follow us on LinkedIn,  X,  Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Contact Information

Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474

View the original press release on ACCESS Newswire

BERLIN, DE / ACCESS Newswire / December 10, 2025 / Treasury Intelligence Solutions (TIS), a leading cloud-based platform for payments and cash management, is future-proofing organizations with specialized translation services in the wake of the recent November 2025 ISO 20022 deadline. A major turning point for the financial industry, SWIFT now requires banks to move their cross-border payment messages to ISO 20022. As a result, treasury teams are already seeing differences in how their banks send and receive payment information. Adapting to these changes will require a strategic approach to modernizing systems and processes.

ISO 20022 replaces a patchwork of older standards with a single approach to structuring payment data. The new universal standard is designed to reduce confusion across markets, improve data quality, and support the level of transparency that regulators around the globe now expect.

Moving to ISO 20022 payments takes time and strategic vision, especially when legacy systems, ERP, and payment systems were not built with structured data in mind. Updating those requires planning and coordination across several internal teams.

“ISO 20022 is a major industry shift, but it shouldn’t disrupt the way companies operate day-to-day,” said Wouter De Bie, Chief Technology Officer at TIS. “Our priority is making this transition seamless. By leveraging our platform’s ability to translate payment files into bank-specific formats and automatically populate ISO-required fields, we give treasury teams the flexibility to adapt at their own pace. This approach ensures stability, reduces risk, and empowers organizations to meet new standards without costly system overhauls or last-minute fixes.”

The TIS platform leverages more than 140,000 bank-specific profiles to provide comprehensive coverage of ISO bank formats. In addition, an innovative AI-powered solution addresses ISO-specific requirements such as structured address information for corporate beneficiaries. Companies that begin now to update their data and payment workflows will be better prepared for the larger changes still ahead. Those that don’t may face frustrating problems like message truncation, rejected payments, and slower processing times as unstructured formats are phased out.

“We’re already seeing the benefits of a proactive approach to ISO 20022,” said Jon Paquette, Chief of Strategy at TIS. “Organizations using our platform have implemented early bank-driven changes without payment failures or costly rework and are also leveraging our statement format conversion capabilities to avoid disruptions in reconciliation and cash applications as banks sunset MT formats and introduce CAMT. This proves that with the right tools, companies can prepare for full ISO adoption on their own timelines – maintaining stability while meeting evolving standards.”

About TIS

TIS helps CFOs, Treasurers, and Finance teams transform their global cash flow, liquidity, and payment functions. Since 2010, our award-winning cloud platform and best-in-class service model have empowered the entire office of the CFO to collaborate more effectively and attain maximum efficiency, automation, and control. TIS enables users to achieve superior performance in key areas surrounding cash forecasting, working capital, outbound payments, financial messaging, fraud prevention, payment compliance, and more.

To learn how TIS can support your ISO 20022 transition, contact us today.

CONTACT:
Blair Romain
+496227698240
blair.romain@tispayments.com

SOURCE: Treasury Intelligence Solutions

View the original press release on ACCESS Newswire

Company Projects Substantial Net Income Expansion Supported by Debt-Free Balance Sheet, ~ $4M Yerbaé Contribution, and Majority Revenue Interest in BONK.fun

SCOTTSDALE, AZ / ACCESS Newswire / December 10, 2025 / Bonk, Inc. (NASDAQ:BNKK) today announced financial guidance for fiscal 2026, projecting a baseline of 100% year-over-year revenue growth. This outlook follows a year of capital reorganization, elimination of legacy liabilities, and activation of higher-margin revenue streams tied to the Company’s digital asset infrastructure.

Following the reverse stock split, effective Thursday, December 11, Bonk, Inc. will enter 2026 with a streamlined capital structure intended to support sustainable, profitable expansion. The restructuring completes a comprehensive, year-long transformation.

2026 Outlook – Key Growth Drivers

• BONK.fun (Digital Asset Revenue): Bonk, Inc. now holds a 51% revenue interest in BONK.fun. Based on valuation metrics established in the Company’s most recent quarterly filing, this asset represents an implied total value of approximately $30 million. Unlike passive-asset treasuries, BONK.fun operates as an active “revenue flywheel,” converting ecosystem activity into recurring cash flow. New product launches scheduled for late Q4 2025 are expected to materially increase recurring, high-margin revenue beginning in 2026.

• Beverage Division (Yerbaé): The Yerbaé brand is expected to contribute roughly $4 million in revenue in 2026. With legacy acquisition debts fully paid, the beverage segment is transitioning from a cost center to a profitable business line.

Potential Revenue Upside & Legislative Catalysts Management emphasizes that the projected 100% year-over-year revenue growth rate represents a prudent baseline that does not fully factor in potential exponential growth driven by the shifting U.S. legislative landscape.

• Strategic Reserve Framework (GENIUS Act of 2025): The Company highlights the impact of the GENIUS Act, enacted in July 2025, which established the framework for a national Strategic Digital Asset Reserve. Bonk, Inc. believes this landmark legislation validates the corporate treasury model it has pioneered, driving unprecedented institutional demand for digital assets.

• Regulatory Clarity (FIT21): The advancement of the Financial Innovation and Technology for the 21st Century Act (FIT21) signals a move toward a clearer regulatory framework. Bonk, Inc. anticipates that such clarity will unlock institutional liquidity and increase transaction velocity across the sector-directly benefiting the fee-generation mechanics of BONK.fun.

Corporate Strengths and Market Catalysts

• Strengthened Governance: The Board has been refreshed with domain-experienced directors, including Connor Klein (New Form Capital), Stacey Duffy (financial due diligence), and Jamie McAvity (CEO, Cormint, Inc.). Their expertise in decentralized finance, capital markets, and high-growth operations supports improved oversight and execution.

• Valuation Strength (mNAV): The Company highlights a current mNAV of 1.85x (Market Cap ÷ BONK Holdings). This ratio demonstrates that the market assigns significant premium value to the Company’s active revenue engines (BONK.fun and Yerbaé) beyond the baseline value of its digital asset treasury, distinguishing Bonk, Inc. from purely passive holding companies.

• Institutional Access and NAV Support: The recent launch of a regulated BONK ETP on the SIX Swiss Exchange broadens institutional access to the underlying asset. Management expects improved institutional awareness and demand to support appreciation of the Company’s treasury holdings and contribute to NAV expansion in 2026.

Balance Sheet and Profitability Improvements

• Debt Elimination: In 2025, the Company materially reduced liabilities and settled legacy obligations. Entering 2026 debt-free will lower interest expense and reduce cash drag, supporting margin improvement and cash flow generation.

• Capital Alignment: The reverse stock split aligns share count with the Company’s reconstituted market capitalization, improving comparability for EPS metrics and institutional participation.

Management Commentary “We recognize yesterday’s market reaction to the 1-for-35 reverse stock split and the associated share price move,” said Jarrett Boon, CEO of Bonk, Inc. “Reverse splits often cause short-term volatility; however, the action was necessary to meet Nasdaq capital structure considerations and to position the Company for institutional coverage and deeper liquidity. Post-split, Bonk, Inc. will have an estimated 5.3 million shares outstanding, a materially reduced float, and no legacy debt. We believe these changes, combined with our majority revenue participation in BONK.fun and the expected $4M contribution from Yerbaé, create a clearer path to durable cash flow and NAV expansion.”

Boon continued, “This pivot has been executed from a forward-thinking landscape designed to capture digital growth with one of the best digital assets on the Solana Blockchain. With legacy liabilities settled, a debt-free balance sheet, and growing contributions from our active revenue engines, our 2026 guidance is grounded in concrete assets and executable revenue streams-not speculation. We expect the coming year to validate our strategy through measurable financial performance.”

About Bonk, Inc. Bonk, Inc. (NASDAQ:BNKK) is a company evolving to bridge the gap between traditional public markets and the digital asset ecosystem. Through its subsidiary BONK Holdings LLC, the Company executes a strategy focused on acquiring revenue-generating assets within the decentralized finance space. The Company also operates a growing beverage division holding the patented Sure Shot and Yerbaé brands.

Investor Relations Contact: Phone: 888.257.8061 Email: investors@bonkdat.com

Forward-Looking Statements: This press release contains forward-looking statements regarding the Company’s projected revenue, net income, and business operations for 2026. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially due to factors such as market volatility in the digital asset sector, consumer demand for beverage products, the performance of the BONK.fun platform, and other risks detailed in Bonk, Inc.’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements.

SOURCE: Bonk, Inc.

View the original press release on ACCESS Newswire

Incubated for DoD & Intelligence use cases, startup announces commercial availability of enterprise AI platform, delivering the fastest path to secure production AI

ARLINGTON, MA / ACCESS Newswire / December 10, 2025 / Axonis, the federated AI infrastructure platform that enables enterprises to run AI directly on distributed, sensitive, and real-time production data, today emerged from stealth with a production-ready architecture that brings AI to any data, wherever it lives. The company also announced the appointment of Todd Barr as Chief Executive Officer. Barr, formerly of Red Hat, Chainlink, and GitLab, will lead Axonis as it commercializes its DoD-hardened architecture for the enterprise market. Barr joins technical founders David Bauer, PhD, and Chris Yonclas, distributed systems and AI/ML experts for the US Army, DARPA, and multiple US government cloud, intelligence, and digital transformation initiatives.

Axonis leadership: Todd Barr, CEO; Aimee D’Onofrio, COO; Chris Yonclas, Co-founder & CPO; David Bauer, PhD, Co-founder & CTO

The Axonis platform introduces a new architectural model that brings AI to the data, eliminating the need for data migration or duplication and delivering secure, immediate, and scalable AI for training, fine-tuning, and deploying models across cloud, on-prem, and edge environments. Axonis complements and protects existing cloud and data lake investments by providing a parallel path that enables organizations to act on raw, real-time data immediately, without slowing down or rethinking their centralization strategy.

As Barr leads Axonis into its commercialization phase following two years of incubation within a US government military contractor (T2S Solutions, part of the Madison Dearborn portfolio), the company is now fully independent and positioned to address one of the biggest barriers in AI adoption: operationalizing AI on data that is too fragmented, regulated, or mission-critical to move.

“Enterprises are quickly realizing that the real barrier to AI isn’t modeling; it’s getting AI models into production,” said Matt Norton, Partner and Head of Technology & Government at Madison Dearborn. “Axonis solves this problem at the architectural level, and Todd has the go-to-market experience to bring that solution to market at scale.”

Data Centralization: Where AI Works in Theory, Not Practice

Enterprises continue to struggle with taking models from proof of concept to production because some of their most valuable data-transactions, customer data, logs, sensor streams, images, and other real-time signals-cannot be moved to a centralized environment. Regulatory constraints, cost, latency, and operational risk make traditional data centralization strategies slow, expensive, and often impossible to fully achieve. As a result, AI adoption stalls at the exact moment organizations attempt to deploy models into mission-critical workflows.

Axonis Architecture: Bring AI to the Data

Axonis solves this production bottleneck with a federated AI architecture that executes models directly where data is generated and governed. Instead of moving terabytes of sensitive data, Axonis moves lightweight models, enabling:

• Training, fine-tuning, and inference on live production data

• Streamlined ELT at runtime for both training and inference

• Real-time intelligence across distributed, centralized, and edge environments

• Secure execution without creating new data copies

• Model collaboration across organizations without sharing raw or sensitive data

This model-to-data approach dramatically reduces data movement, improves model freshness, and unlocks up to 12x faster time-to-AI value.

“After the ChatGPT-style quick wins, enterprises are realizing that they have an architecture problem standing in the way of true business transformation with AI,” said Barr. “Axonis delivers a secure, AI-ready architecture for data and AI compute that will underpin and unlock the business transformation possible by GenAI and agents, without having to run a big IT data centralization project to get there.”

Engineered for Defense, Built for Enterprise Scale

Axonis’ architecture originated inside T2S Solutions to support the U.S. Department of Defense and Intelligence Community, where systems must operate under extreme constraints:

• Intelligence must be close to the data

• Data security is survival

• Connectivity is limited or intermittent

• Data is chaotic and everywhere

• Every action must be governed and auditable

These requirements shaped Axonis into a high-assurance platform that meets and exceeds the security, sovereignty, and operational demands of industries such as healthcare, financial services, insurance, manufacturing, critical infrastructure, and the public sector.

“We’ve spent the better part of six years engineering the AI architecture in Axonis that will support environments where failure isn’t an option,” said David Bauer, Chief Technology Officer and technical co-founder of Axonis. “Those same capabilities-distributed execution, zero-trust security, and model-to-data design-are exactly what enterprises now need to safely and reliably run AI in production.”

Built to Integrate, Designed to Collaborate

Axonis is a cloud-native enterprise solution that fits seamlessly into existing enterprise data and AI ecosystems, including Snowflake, Databricks, MinIO, Iceberg, Jupyter, and leading AI frameworks. The platform also unlocks a new model of cross-organization collaboration: teams can share intelligence without sharing or pooling data, allowing each party to benefit from federated learning while keeping sensitive information fully protected. Because Axonis applies security at the data level, even agentic AI systems and chatbots cannot access or act on information they are not authorized to see, bringing a new level of control and data protection to enterprise AI deployments.

About Axonis
Axonis brings AI to the data, wherever that data lives. Originally developed inside a US government solutions provider to the U.S. Department of Defense and Intelligence Community, Axonis enables secure, real-time AI on production, operational, sovereign, and edge data without moving the data. Axonis accelerates time-to-AI value while providing zero-trust, data-level security, and enabling cross-organization AI collaboration without sharing data.

For more information, visit axonis.ai.

Press Contact

Kristin Canders
207-974-7744
kristin@grithaus.agency

###

SOURCE: Axonis

View the original press release on ACCESS Newswire